1-溴-3-氟-5-硝基苯 | 7087-65-2

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯胺系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-溴-3-氟-5-硝基苯
• 中文别名: 3-溴-5-氟苯胺；1-溴-3-氟-5?-硝基苯
• 英文名称: 1-bromo-3-fluoro-5-nitrobenzene
• 英文别名: 1-nitro-3-fluoro-5-bromo benzene
• CAS: 7087-65-2
• 化学式: C₆H₃BrFNO₂
• 分子量: 219.998
• InChiKey: SWXVEPMSQBEVRH-UHFFFAOYSA-N

物化性质

• 沸点：
  247.2±20.0 °C(Predicted)
• 密度：
  1.808±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  6.1
• 海关编码：
  2904909090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Bromo-3-fluoro-5-nitrobenzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H331: Toxic if inhaled
H302: Harmful if swallowed
H312: Harmful in contact with skin
Causes skin irritation
H315:
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Bromo-3-fluoro-5-nitrobenzene
CAS number: 7087-65-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H3BrFNO2
Molecular weight: 220.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2810 Class: 6.1 Packing group: III
Proper shipping name: TOXIC, LIQUIDS, ORGANIC, N.O.S. OR TOXIC, LIQUIDS, ORGANIC, N.O.S. INHALA-
TION HAZARD, PACKING GROUP I, ZONE A OR B (1-Bromo-3-fluoro-5-nitrobenzene)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-溴-3-氟-5-硝基苯 在 palladium on activated charcoal 盐酸 、 硫酸 、 氢气 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 150.0 ℃ 、193.05 kPa 条件下， 反应 7.2h， 生成 3-amino-5-fluorobenzoic acid hydrochloride
  参考文献：
  名称：

  Directed biosynthesis of 5''-fluoropactamycin in Streptomyces pactum.

  摘要：

  一种新的孔雀霉素类似物5"-氟孔雀霉素通过定向生物合成法制备而成。通过在孔雀霉素链霉菌（Streptomyces pactum）发酵培养基中添加3-氨基-5-氟苯甲酸（3-amino-5-fluorobenzoic acid），这种化合物是3-氨基苯甲酸的类似物，而3-氨基苯甲酸是孔雀霉素生物合成中的一种高级前体，从而导致了孔雀霉素和新的孔雀霉素类似物的共同生产。与3-氨基-5-甲基苯甲酸的类似喂养实验未能产生相应的甲基化孔雀霉素类似物，仅导致了孔雀霉素生产的抑制。对孔雀霉素和5"-氟孔雀霉素的抗菌和细胞毒活性比较显示没有显著差异。

  DOI：

  10.7164/antibiotics.47.1456
• 作为产物：
  描述：

  2-溴-4-氟-6-硝基苯胺 在 copper(I) oxide 、 硫酸 、 亚膦酸 、 sodium nitrite 作用下， 生成 1-溴-3-氟-5-硝基苯
  参考文献：
  名称：

  Directed biosynthesis of 5''-fluoropactamycin in Streptomyces pactum.

  摘要：

  一种新的孔雀霉素类似物5"-氟孔雀霉素通过定向生物合成法制备而成。通过在孔雀霉素链霉菌（Streptomyces pactum）发酵培养基中添加3-氨基-5-氟苯甲酸（3-amino-5-fluorobenzoic acid），这种化合物是3-氨基苯甲酸的类似物，而3-氨基苯甲酸是孔雀霉素生物合成中的一种高级前体，从而导致了孔雀霉素和新的孔雀霉素类似物的共同生产。与3-氨基-5-甲基苯甲酸的类似喂养实验未能产生相应的甲基化孔雀霉素类似物，仅导致了孔雀霉素生产的抑制。对孔雀霉素和5"-氟孔雀霉素的抗菌和细胞毒活性比较显示没有显著差异。

  DOI：

  10.7164/antibiotics.47.1456

文献信息

• [EN] HETEROCYCLIC INHIBITORS OF PCSK9<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE PCSK9
  申请人：CARDIO THERAPEUTICS PTY LTD

  公开号：WO2018165718A1

  公开（公告）日：2018-09-20

  This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and formulations comprising such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I): (I) wherein A, D and Q are described herein.

  这种应用涉及可能作为PCSK9的抑制剂或以其他方式调节PCSK9活性的化合物，或其药用可接受的盐、溶剂化合物、前药或多型体，以及包含这些化合物的组合物和配方，以及使用和制备这些化合物的方法。化合物包括式(I)的化合物：(I)其中A、D和Q如本文所述。
• BROMODOMAIN INHIBITORS
  申请人：Quanticel Pharmaceuticals

  公开号：US20150111885A1

  公开（公告）日：2015-04-23

  The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.

  本发明涉及替代杂环衍生物化合物，包括所述化合物的组合物，以及通过抑制溴结构域介导的蛋白质乙酰赖氨酸区域的识别来进行表观遗传调控的所述化合物和组合物的用途。所述组合物和方法对于癌症和肿瘤性疾病的治疗是有用的。
• Cyclocarbamate derivatives as progesterone receptor modulators
  申请人：——

  公开号：US20020049204A1

  公开（公告）日：2002-04-25

  This invention provides compounds of Formula (I): 1 wherein R 1 and R 2 may be single substituents or fused to form spirocyclic or hetero-spirocyclic rings; R 3 is H, OH, NH 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 3 to C 6 alkenyl, substituted C 1 to C 6 alkenyl, alkynyl, or substituted alkynyl, COR C ; R C is H, C 1 to C 3 alkyl, substituted C 1 to C 3 alkyl, aryl, substituted aryl, C 1 to C 3 alkoxy, substituted C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, or substituted C 1 to C 3 aminoalkyl; R 4 is H, halogen, CN, NO 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, alkynyl, or substituted alkynyl, C 1 to C 6 alkoxy, substituted C 1 to C 6 alkoxy, amino, C 1 to C 6 aminoalkyl, or substituted C 1 to C 6 aminoalkyl; and R 5 is selected from a trisubstituted benzene ring of a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO 2 or NR 6 and containing one or two independent substituents from the group including H, halogen, CN, NO 2 , amino, and C 1 to C 3 alky, C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, COR F , or NR G COR F ; or pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods using the compounds as antagonists of the progesterone receptor.

  这项发明提供了Formula (I)的化合物： 其中R1和R2可以是单个取代基或融合形成螺环或杂环螺环；R3为H、OH、NH2、C1到C6烷基、取代的C1到C6烷基、C3到C6烯基、取代的C1到C6烯基、炔基或取代的炔基、CORC；RC为H、C1到C3烷基、取代的C1到C3烷基、芳基、取代的芳基、C1到C3烷氧基、取代的C1到C3烷氧基、C1到C3氨基烷基或取代的C1到C3氨基烷基； R4为H、卤素、CN、NO2、C1到C6烷基、取代的C1到C6烷基、炔基或取代的炔基、C1到C6烷氧基、取代的C1到C6烷氧基、氨基、C1到C6氨基烷基或取代的C1到C6氨基烷基；R5从包括O、S、SO、SO2或NR6的1、2或3个杂原子的五元或六元环的三取代苯环中选择，并含有来自包括H、卤素、CN、NO2、氨基和C1到C3烷基、C1到C3烷氧基、C1到C3氨基烷基、CORF或NRGCORF的一个或两个独立取代基；或其药学上可接受的盐，以及将这些化合物用作孕激素受体拮抗剂的药物组合物和方法。
• Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site
  作者：Marcel Günther、Jonas Lategahn、Michael Juchum、Eva Döring、Marina Keul、Julian Engel、Hannah L. Tumbrink、Daniel Rauh、Stefan Laufer

  DOI：10.1021/acs.jmedchem.7b00316

  日期：2017.7.13

  strategies in the treatment of lung cancer. Acquired resistance compromises the clinical efficacy of EGFR inhibitors during long-term treatment. The recently discovered EGFR-C797S mutation causes resistance against third-generation EGFR inhibitors. Here we present a rational approach based on extending the inhibition profile of a p38 MAP kinase inhibitor toward mutant EGFR inhibition. We used a privileged

  表皮生长因子受体的抑制代表了肺癌治疗中最有希望的策略之一。在长期治疗期间，获得性耐药会损害EGFR抑制剂的临床疗效。最近发现的EGFR-C797S突变引起对第三代EGFR抑制剂的耐药性。在这里，我们基于将p38 MAP激酶抑制剂的抑制谱向突变EGFR抑制扩展的基础上，提出了一种合理的方法。我们使用了一种特权支架，该支架具有经过验证的细胞效力以及体内功效和低毒性。在分子建模的指导下，我们合成并研究了40种化合物与临床相关EGFR突变体的结构-活性关系。我们使用针对吉非替尼耐药的T790M突变细胞系的共价结合抑制剂，成功地将细胞EGFR抑制作用降低至低纳摩尔范围。我们确定了其他非共价相互作用，这使我们能够开发对奥西替尼耐药的L858R / T790M / C797S突变体具有高活性的代谢稳定抑制剂。
• NMDA antagonists
  申请人：Merrell Pharmaceuticals Inc.

  公开号：US05606063A1

  公开（公告）日：1997-02-25

  The present invention is directed to a new class of 4-sulfanimide-quinoline derivatives and to their use as NMDA antagonists.

  本发明涉及一类新的4-磺胺基喹啉衍生物，以及它们作为NMDA拮抗剂的用途。